New Recruiting Trial: Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)
WHY IT MATTERS
This trial offers patients with moyamoya disease or cerebral amyloid angiopathy who have had a stroke access to personalized, AI-guided prevention strategies that could reduce their risk of future strokes.
Researchers are testing a new technology called 'digital twins' to help prevent second strokes in patients with three rare brain conditions: moyamoya disease, cerebral amyloid angiopathy, and previous stroke history. A digital twin is a computer model of a patient's brain that doctors can use to predict what treatments might work best for that individual. This study will randomly assign patients to either receive care guided by this digital twin technology or standard care, and compare which approach prevents more strokes.
NCT ID: NCT06714097 Title: Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project) Status: RECRUITING Phase: NA Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT06714097 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have moyamoya disease, cerebral amyloid angiopathy, or a history of stroke, check the trial's eligibility criteria at clinicaltrials.gov/study/NCT06714097 and contact the sponsor (Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta) to learn if you qualify and how to enroll before recruitment closes.